Thermo Fisher Scientific reported $46.3B of revenue over the trailing twelve months, +7.2% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $46.3B (to Q2 2026). Net income: $6.97B, trailing twelve months to Q2 2026. Free cash flow: $7.32B, trailing twelve months to Q2 2026. Operating margin: 18%, trailing twelve months to Q2 2026.

TMOThermo Fisher Scientific

Healthcare

$657.83+37% 1Y

$657.83

$437.9052 weeks$679.96

TMO as reported

Thermo Fisher Scientific reported $46.3B of revenue over the trailing twelve months, +7.2% on the year before. 11 reported series are charted on this page, each one as filed.

$46.3B

Revenue, trailing twelve months · to Q2 2026 · +7.2% against the twelve months before

Net income: $6.97B
Net income · +5.8% year on year · trailing twelve months to Q2 2026
Free cash flow: $7.32B
Free cash flow · +19% year on year · trailing twelve months to Q2 2026
Operating margin: 18%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TMO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$46.3B	+7.2%	Q2 2026
Net income	$6.97B	+5.8%	Q2 2026
EPS	$18.59	+7.5%	Q2 2026
Gross margin	44%	n/a	Q4 2019 · 26 quarters behind
Operating margin	18%	n/a	Q2 2026
Net margin	15%	n/a	Q2 2026
ROE	13%	n/a	Q2 2026
ROA	6.2%	n/a	Q2 2026
ROIC	7.1%	n/a	Q2 2026
Free cash flow	$7.32B	+19%	Q2 2026
P/E	35.4	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.